TXLC also focused on regulating ubiquitin to adjust the C-reactive protein levels and inflammation-related pathways to exert anti-inflammatory effects as well as improving hypoxia to protect myocardial cells in CHD patients [17]. This evidence concerns the gene CRP and coronary artery disorder.